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Abstract
Despite evidence supporting the effectiveness of best practices in infection prevention and management, many
healthcare workers fail to implement them and evidence-based practices tend to be underused in routine practice.
Prevention and management of infections across the surgical pathway should always focus on collaboration among
all healthcare workers sharing knowledge of best practices. To clarify key issues in the prevention and management
of infections across the surgical pathway, a multidisciplinary task force of experts convened in Ancona, Italy, on May
31, 2019, for a national meeting. This document represents the executive summary of the final statements
approved by the expert panel.
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Background
Prevention and management of infections across the sur-
gical pathway should always focus on collaboration
among all healthcare professionals with shared know-
ledge and widespread diffusion of best practices.
Leading international organizations, such as the World
Health Organization (WHO), acknowledge that collab-
orative practice is essential for achieving a concerted ap-
proach to providing care that is appropriate to meet the
needs of patients, thus optimizing individual health out-
comes and overall service delivery of healthcare [1].
Methods
To clarify key issues in the prevention and management
of infections across the surgical pathway, a multidiscip-
linary task force of national experts convened in Ancona,
Italy, on May 31, 2019, for a national meeting. The
multifaceted nature of these infections has led to a
multidisciplinary collaboration involving epidemiologists
and infection control specialists, infectious disease spe-
cialists, hospital pharmacists, microbiologists, intensi-
vists, general and emergency surgeons, and nurses.
During the meeting, the panelists presented the state-
ments developed for each of the main questions regard-
ing the prevention and management of infections in
surgery. An agreement on the statements was reached
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by the Delphi method. Statements were approved with
an agreement of ≥ 80%. After the meeting, the expert
panel met via email to prepare and revise the consensus
paper resulting from the meeting. The manuscript was
successively reviewed by all members and ultimately re-
vised as the present manuscript. This document repre-
sents the executive summary of the final statements
approved by the expert panel.
Healthcare-associated infections and patient
safety
Improving patient safety in hospitals worldwide pres-
ently requires a systematic approach to preventing
healthcare-associated infections (HAIs) and antimicro-
bial resistance (AMR). The two go together. HAIs are in-
fections that occur while receiving healthcare. Patients
with medical devices (central lines, urinary catheters,
ventilators) or who undergo surgical procedures are at
risk of acquiring HAIs.
The occurrence of HAIs continues to escalate at an
alarming rate. These infections result in significant pa-
tient illnesses and deaths, prolong the duration of hos-
pital stay, and necessitate additional diagnostic and
therapeutic interventions, which generate supplementary
costs to those already sustained due to the patient’s
underlying disease. However, the phenomenon is not yet
sufficiently perceived among both healthcare workers
(HCWs) and patients, thus resulting in a low level of
intervention request and relative inadequate responses
[2]. Although HAIs are the most frequent adverse events
in healthcare, their true global burden remains unknown
because of the difficulty in gathering reliable data: most
countries lack surveillance systems for HAIs, and those
do have them struggle with the complexity and the lack
of uniformity of criteria [3].
HAIs are considered adverse events, and as many are
preventable, they are considered an indicator of the
quality of patient care and a patient safety issue. In 2018,
a systematic review and meta-analysis of studies between
2005 and 2016 evaluated the results of multifaceted in-
terventions to reduce catheter-associated urinary tract
infections (CAUTIs), central line-associated bloodstream
infections (CLABSIs), surgical site infections (SSIs),
ventilator-associated pneumonia, and hospital-acquired
pneumonia not associated with mechanical ventilation in
acute care or long-term care settings [4]. Of the 5226 ar-
ticles identified, 144 studies were included in the final
analysis. Published evidence suggested a sustained po-
tential for the significant reduction of HAI rates in the
range of 35–55% associated with multifaceted interven-
tions irrespective of a country’s income level.
Question 1. How can you implement global guide-
lines for the prevention of surgical site infections
(SSIs)?
Statement 1.1. Recent global guidelines for the pre-
vention of SSIs can support healthcare workers to de-
velop or strengthen infection prevention and control
programs, with a focus on surgical safety, as well as
AMR action plans. All healthcare workers should
adopt these evidence-based recommendations in
their clinical practice.
Statement 1.2. A safer surgical care requires a range
of precautions aimed at reducing the risk of SSIs be-
fore, during and after surgery.
Statement 1.3. To support local implementation of
guidelines for the prevention of SSIs, 5 steps of a
multimodal strategy, including system change, train-
ing and education, evaluation and feedback, commu-
nications for awareness raising and institutional
safety climate and culture are suggested.
Improving behavior in infection prevention and con-
trol (IPC) practices remains a challenge. Despite pro-
gress in preventive knowledge, SSIs remain the most
common HAI among surgical patients and one of the
most frequent adverse events in hospitals. They repre-
sent a major clinical problem in terms of morbidity,
mortality, length of hospital stay, and overall direct and
not direct costs worldwide. It is obviously important to
improve patient safety by reducing the occurrence of
SSIs. Preventing SSIs is a global priority, also because
bacteria are becoming increasingly resistant to antibi-
otics, making SSI prevention even more important now-
adays. On the other hand, SSI prevention is complex
and requires the integration of a range of measures be-
fore, during, and after surgery.
Both WHO [5, 6] and the Centers for Disease Control
and Prevention (CDC) [7] have published guidelines for
the prevention of SSIs. The 2016 WHO Global guide-
lines for the prevention of SSI [5, 6] are evidence-based
including systematic reviews presenting additional infor-
mation in support of actions to improve practice. The
first-ever global guidelines for the prevention of SSIs
were published on November 3, 2016, then were up-
dated in some parts and published in a new edition in
December 2018. The guidelines include 13 recommen-
dations for the preoperative period and 16 for preventing
infections during and after surgery. They range from
simple precautions such as ensuring that patients bathe
or shower before surgery, appropriate way for surgical
teams to clean their hands, guidance on when to use
prophylactic antibiotics, which disinfectants to use be-
fore incision, and which sutures to use.
The proposed recommendations are classified as
follows:
 “Strong”: Expert panel was confident that benefits
outweighed risks, considered to be adaptable for
implementation in most (if not all) situations, and
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patients should receive intervention as a course of
action.
 “Conditional”: Expert panel considered that benefits
of intervention probably outweighed the risks; a
more structured decision-making process should be
undertaken, based on stakeholder consultation and
involvement of patients and healthcare professionals.
In 2018, WHO published a document about the im-
plementation approaches for these evidence-based rec-
ommendations [8]. The purpose of this document is to
present a range of tested approaches to achieve success-
ful SSI prevention implementation at the facility level,
including in the context of a broader surgical safety cli-
mate, using an evidence- and team-based approach and
a multimodal strategy for achieving sustainable change
based on system change, training and education, evalu-
ation and feedback, communications for awareness rais-
ing, and institutional safety climate and culture. The
manual is aimed at all those concerned with the preven-
tion of SSIs. A multidisciplinary team is necessary to
successfully implement preventive measures. This should
include at least IPC and associated staff, such as those
working in epidemiology, decontamination/sterilization,
quality improvement and patient safety, hospital admin-
istration, and the surgical teams (including surgeons, an-
esthesiologists, and perioperative nurses).
Question 2. Why do you have to survey HAIs?
Statement 2.1. Surveillance of HAIs improves the
quality of care because it reduces the risk of infection.
It should be supported by all healthcare workers.
IPC program should be in place to prevent HAIs in all
hospitals worldwide, and one of the main cornerstones
is the presence of a formal system to monitor IPC and
ensure that appropriate actions are taken to minimize
infection rates [9]. HAI surveillance is a challenging task
also because it requires particular expertise after obtain-
ing epidemiological data to assess the quality of the in-
formation produced and to interpret its meaning and
root cause in order to tailor intervention and prevention
measures.
Program surveying SSIs have been implemented
throughout the world and are associated with a reduc-
tion in SSI rates. Data on non-prosthetic surgery from
the Italian SSI surveillance program for the period 2009
to 2011 [10] demonstrated that implementation of a na-
tional surveillance program was helpful in reducing SSI
rates and should be prioritized in all healthcare systems.
A 17% decrease in SSI related to ten selected procedures
was reported between 2008 and 2013 in the USA follow-
ing improvement programs [11]. In African hospitals, a
60% SSI risk reduction was observed following the im-
plementation of a WHO multimodal strategy in the con-
text of the WHO Surgical Unit-based Safety Program
(SUSP) including SSI surveillance [12]. Surveillance also
allows hospitals and clinicians to measure the effective-
ness of strategies that are implemented to decrease in-
fection rates. Infection rate data should be used in a
positive way to improve the quality and safety of
healthcare.
HAI surveillance is conventionally conducted by
two methods. Passive surveillance (self-reporting of
suspected HAIs by the treating physicians) is a very
poor and inefficient method to track HAIs as there
is a risk of bias and underreporting. Active surveil-
lance, on the other hand, is the systematic collection
of data by a designated unbiased surveillance team.
This is the method recommended by the main sur-
veillance networks. Following the data extraction,
analysis of the collected information should be done.
Feedback and reports after the analysis should be
disseminated by infection control committees, keep-
ing the confidentiality of individuals. The import-
ance of surveillance systems for HAI control has
been accepted globally, and some countries have
established national surveillance systems with the
aim to prevent HAIs.
Question 3. How can you implement the prevention
of HAIs?
Statement 3.1. It is necessary to set up a solid and
branched surveillance network gathering alert sig-
nals, verifying their severity and initiating the
organizational response via “warnings”.
Statement 3.2. The collection and analysis of moni-
toring data serve to identify vulnerabilities in the sys-
tem. This is the basis for organizational improvement,
risk reduction, and damage control.
HAIs affect around 5–15% of all hospital patients
worldwide. Despite the availability of standard proce-
dures and evidence-based guidelines aiming at reducing
the impact of HAIs, the implementation of those into
routine practice appears as the biggest challenge [13].
HAI surveillance and timely feedback of results are
strongly recommended by WHO as part of the core
components of effective IPC programs [14]. Every
healthcare facility should be committed to provide qual-
ity and safe care. Surveillance is not to be undertaken in
isolation, but as integrated into a comprehensive and
multimodal IPC strategy. Conducting high-quality IPC
and surveillance is crucial to assess the safety level of the
surgical workflow, detect criticalities, and diffuse warn-
ings to trigger the response capability of healthcare orga-
nizations. Feedback on IPC achievements should be
constantly monitored and timely disseminated through-
out the levels of the organization by the hospital IPC
[15]. Surveillance of HAIs is a fundamental aspect of the
IPC program, in particular, when SSIs are identified as a
target for improvement.
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Particularly in surgical care, SSI surveillance pro-
vides feedback to surgical teams on the HAI risks
patients are exposed to. Cooperation of surgical
teams in surveillance efforts is crucial to make vis-
ible to them the effect on patients’ care, if they
have confidence in the methods being used. Thus,
it is important for surgeons to comprehend the op-
portunities of the surveillance process for surgical
care improvements [15]. In this regard, the support
of human factors and ergonomics paired with im-
plementation science is crucial to embed the know-
ledge gained through an epidemiological into the
daily routine of HCWs [16].
Question 4. How can you prevent and manage Clos-
tridioides difficile infection (CDI)?
Statement 4.1. Key points for CDI prevention are:
 Antimicrobial stewardship.
 Contact precautions.
 Hand washing (soap, not alcohol).
 Avoid unnecessary gastric acid suppressants.
Statement 4.2. Key points for CDI treatment are:
 Stop unnecessary antibiotics.
 Metronidazole (mild episodes).
 Oral/intracolonic vancomycin.
 Oral fidaxomicin.
 IV bezlotoxumab (recurrent episodes).
 Fecal microbiota transplantation.
 Prompt surgery when indicated.
In the last two decades, CDI has become a major
global public health problem, with a dramatic in-
crease in the incidence and severity of episodes.
CDI may be a particular concern in surgical pa-
tients, as surgery may predispose patients to CDI
and surgery itself could be necessary to treat severe
cases of CDI [17].
Risk factors for CDI may be divided into three general
categories [17]:
1. Host factors (immune status, co-morbidities)
2. Exposure to C. difficile spores (hospitalizations,
community sources, long-term care facilities)
3. Factors that disrupt normal colonic microbiome
(antibiotics, other medications, surgery)
The main risk factors are antibiotic exposure, age
more than 65 years, comorbidity or underlying condi-
tions, inflammatory bowel diseases, immunodeficiency
(including human immunodeficiency virus infection),
malnutrition, and low serum albumin level. Antibiotics
play a central role in the pathogenesis of CDI, presum-
ably by disrupting the normal gut flora, thereby provid-
ing a perfect setting for C. difficile to proliferate and
produce toxins. Although nearly all antibiotics have been
associated with CDI, clindamycin, third-generation
cephalosporins, penicillins, and fluoroquinolones have
usually been considered at greatest risk [16].
A prompt and precise diagnosis is an important aspect
of effective management of CDI. Early identification of
CDI allows the establishment of an early treatment and
can improve outcomes. Rapid isolation of infected pa-
tients is fundamental to limit C. difficile transmission.
This is particularly important in reducing environmental
contamination as spores can survive for months in the
environment, despite regular use of environmental
cleaning agents. Patients with CDI should be maintained
in contact (enteric) precautions until the resolution of
diarrhea (passage of formed stool for at least 48 h). Pa-
tients with known or suspected CDI should ideally be
placed in a private room with en suite hand washing and
toilet facilities. If a private room is not available, as often
occurs, known CDI patients may be cohort, nursed in
the same area, though the theoretical risk of transfection
with different strains exists. Hand hygiene with soap and
water and the use of contact precautions along with a
good cleaning and disinfection of the environment and
patient equipment should be used by all HCWs
contacting any patient with known or suspected CDI.
Alcohol-based hand sanitizers are highly effective against
non-spore-forming organisms, but they may not kill C.
difficile spores or remove C. difficile from the hands.
The most effective way to remove them from the hands
is through handwashing with soap and water.
In cases of suspected severe CDI, antibiotic agents
should be discontinued, if possible [18]. A meta-analysis
addressing factors associated with prolonged symptoms
and severe disease due to C. difficile showed that contin-
ued use of antibiotics for infections other than CDI is
significantly associated with an increased risk of CDI re-
currence [18]. If continued antibiotic therapy is required
for the treatment of the primary infection, antimicrobial
therapy with agents that are less frequently implicated
with antibiotic-associated CDI should be used; these in-
clude parenteral aminoglycosides, sulfonamides, macro-
lides, vancomycin, or tetracycline/tigecycline.
Although there is a clinical association between proton
pump inhibitor (PPI) use and CDI [19], no randomized
controlled trial (RCT) studies have studied the relation-
ship between discontinuing or avoiding PPI use and the
risk of CDI. Thus, a strong recommendation to discon-
tinue PPIs in patients at high risk for CDI regardless of
the need for PPIs will require further evidence. However,
stewardship activities to discontinue unneeded PPIs are
strongly warranted.
Regarding treatment, antibiotic therapy is the first
choice for CDI treatment and molecule choice should be
based according to the severity of the disease. When
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antibiotic therapy is indicated for symptomatic cases
with a positive stool C. difficile test, options include
metronidazole, oral or intraluminal vancomycin, and
oral fidaxomicin [20–24]. Metronidazole should be lim-
ited to the treatment of an initial episode of mild-
moderate CDI. Vancomycin orally 125 mg four times
daily for 10 days is considered superior to metronidazole
in severe CDI [25–27]. Doses of up to 500 mg have been
used in patients with severe or fulminant, as defined as
hypotension or shock, ileus, or megacolon, CDI [28], al-
though there is little evidence for this in the literature.
Fidaxomicin orally 200 mg twice daily for 10 days may
be a valid alternative to vancomycin in patients with
CDI [29, 30]. Fidaxomicin may be useful for treating pa-
tients who are considered at high risk for recurrence
(elderly patients with multiple comorbidities who are re-
ceiving concomitant antibiotics).
Fecal microbiota transplantation (FMT) is an effective
option for patients with multiple CDI recurrences who
have failed appropriate antibiotic treatments [31]. FMT
involves infusing intestinal microorganisms (in a suspen-
sion of healthy donor stool) into the intestine of patients
to restore the intestinal microbiota. The rationale of
FMT is that disruption of the normal balance of colonic
flora allows C. difficile strains to grow and produce CDI.
By reintroducing normal flora via donor feces, the imbal-
ance may be corrected and normal bowel function re-
established [31].
Coadjuvant treatment with monoclonal antibodies
(bezlotoxumab) may prevent recurrences of CDI, par-
ticularly in patients with CDI due to the 027 epidemic
strain, in immunocompromised patients and in patients
with severe CDI. Bezlotoxumab (MK-6072), approved in
2016 by Food and Drug Administration (FDA), is a hu-
man monoclonal antibody which reduces recurrent CDI
by blocking the binding of C. difficile toxin B to host
cells, thus limiting epithelial damage and facilitating re-
covery of the microbiome [32].
Patients with severe CDI who progress to systemic
toxicity should undergo early surgical consultation and
should be evaluated for potential surgical intervention.
Resection of the entire colon should be considered to
treat patients with fulminant colitis. However, diverting
loop ileostomy with colonic lavage is a useful alternative
to resection of the entire colon.
Question 5. How can you prevent central-venous
catheter-related infections?
Statement 5.1. The most effective means to reduce to
the minimum possible central-venous catheter-related
infections are represented by a «bundles» management,
based on the guidelines, implemented with training and
motivational meetings aimed at increasing compliance
of healthcare workers (better if organized in a dedicated
team) and applied by checklist.
In order to guarantee a correct management of central
venous catheter-related infections, a correct diagnostic
framework is essential, to be obtained by a standardized
execution of blood cultures from a peripheral vein and
central venous catheter (CVC), in order to be able to im-
plement a correct interpretation of the results and take
timely decisions on a possible removal/conservative
strategy towards the catheter.
About half of nosocomial bloodstream infections occur
in intensive care units (ICUs), and the majority of them
are associated with an intravascular device. Central ven-
ous catheter-related bloodstream infections (CRBSIs) are
an important cause of HAIs. CVCs are integral to mod-
ern clinical practices and are inserted in critically ill pa-
tients for the administration of fluids, blood products,
medication, and nutritional solutions and for
hemodynamic monitoring. They are the main source of
bacteremia in hospitalized patients and therefore should
be used only if necessary.
Risk factors for CRBSIs include patient-, catheter-, and
operator-related factors. Several factors have been pro-
posed to participate in the pathogenesis of CRBSI. Hos-
pitalized patients with neutropenia are at higher risk.
However, other host risk factors also include immune
deficiencies in general, chronic illness, and malnutrition.
The diagnosis of CRBSI is often suspected clinically in a
patient using a CVC who presents with fever or chills,
unexplained hypotension, and no other localizing sign.
Diagnosis of CRBSI requires establishing the presence of
bloodstream infection and demonstrating that the infec-
tion is related to the catheter. However, blood cultures
should not be drawn solely from the catheter port as
these are frequently colonized with skin contaminants,
thereby increasing the likelihood of a false-positive blood
culture. Indeed, according to IDSA guidelines [33], a de-
finitive diagnosis of CRBSI requires a culture of the same
organism from both the catheter tip and at least one
percutaneous blood culture. Alternatively, the culture of
the same organism from at least two blood samples (one
from a catheter hub and the other from a peripheral vein
or second lumen) meeting criteria for quantitative blood
cultures or differential time to positivity. Most laborator-
ies do not perform quantitative blood cultures, but many
laboratories are able to determine the differential time to
positivity. Quantitative blood cultures demonstrating a
colony count from the catheter hub sample ≥ 3-fold
higher than the colony count from the peripheral vein
sample (or a second lumen) supports a diagnosis of
CRBSI. Differential time to positivity refers to growth
detected from the catheter hub sample at least 2 h be-
fore growth detected from the peripheral vein sample.
The CVC and arterial catheter, if present, should be cul-
tured and removed as soon as possible if the patient has
unexplained sepsis or erythema overlying the catheter
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insertion site or purulence at the catheter insertion site
in immunocompromised patients.
Antibiotic therapy for catheter-related infection is
often initiated empirically. The initial choice of antibi-
otics will depend on the severity of the patient’s clinical
disease, the risk factors for infection, and the likely path-
ogens associated with the specific intravascular device.
Resistance to antibiotic therapy due to biofilm formation
also has an important role in the management of
bacteremia. In fact, the nature of the biofilm structure
makes microorganisms difficult to eradicate and confer
an inherent resistance to antibiotics.
CRBSIs can be reduced by a range of interventions in-
cluding closed infusion systems, aseptic technique dur-
ing insertion and management of the central venous
line, early removal of central venous lines, and appropri-
ate site selection. Different measures have been imple-
mented to reduce the risk for CRBSI, including the use
of maximal barrier, precautions during catheter inser-
tion, effective cutaneous anti-sepsis, and preventive
strategies based on inhibiting microorganisms originat-
ing from the skin or catheter hub from adhering to the
catheter [34]. The simultaneous application of multiple
recommended best practices to manage CVCs has been
associated with significant declines in the rates of CRBSI.
Bundles can be defined as the systematic implementa-
tion of a set of evidence-based practices, usually three to
five, that when performed properly and collectively can
improve patient outcomes. Research on CRBSI preven-
tion demonstrated the effectiveness of bundles, which
reduce the incidence of CRBSI by up to 80% [35–37],
reaching a rate of 0 in some cases [38]. Education and
training of healthcare workers and adherence to stan-
dardized protocols for insertion and maintenance of
intravascular catheters significantly reduced the inci-
dence of catheter-related infections and represent the
most important preventive measures.
The global burden of antimicrobial resistance
AMR has emerged as one of the principal public health
problems of the twenty-first century. This has resulted in
a public health crisis of international concern. Combating
resistance has become a top priority for global policy-
makers and public health authorities. New mechanisms of
resistance continue to emerge and spread globally, chal-
lenging our ability to manage common infections. Anti-
bacterial and antifungal use in animal and agricultural
industries aggravates selective pressure on microbes. A
One Health approach is required urgently. Addressing the
rising threat of AMR requires a holistic and multisectoral
approach—referred to as One Health—because antimicro-
bials used to treat various infectious diseases in animals
may be the same or similar to those used for humans.
Resistant bacteria arising in humans, animals, or the
environment may spread from one to another and from
one country to another. AMR does not recognize geo-
graphic or human-animal borders [39].
The worldwide impact of AMR is significant, in terms
of economic and patient outcomes, because of untreat-
able infections or those necessitating antibiotic agents of
last resort leading to increased length of hospital stay,
morbidity, death, and treatment cost. Raising awareness
of AMR and promoting behavioral change through pub-
lic communication programs that target different audi-
ences in human health, animal health, and agricultural
practice, as well as consumers, are critical to tackling
this issue.
HCWs play a central role in preventing the emergence
and spread of resistance. An effective and cost-effective
strategy to reduce AMR should involve a multifaceted
approach aimed at optimizing antibiotic use, strengthen-
ing surveillance and IPC, and improving patient and
clinician education regarding the appropriate use of anti-
biotic agents.
Although the phenomenon of AMR can be attributed
to many factors, there is a well-established relationship
between antimicrobial prescribing practices and the
emergence of antimicrobial-resistant pathogens. How-
ever, after they have emerged, resistant pathogens may
be transmitted from one individual to another. Every in-
fection prevented is one that needs no treatment. Pre-
vention of infection can be cost-effective and
implemented in all settings and sectors, even where re-
sources are limited. A range of factors such as diagnostic
uncertainty, fear of clinical failure, time pressure, or
organizational contexts can complicate both antibiotic
prescribing decisions and preventing measures. Because
of cognitive dissonance (recognizing that action is neces-
sary but not implementing it), however, changing behav-
ior is extremely challenging, and awareness of AMR is
still low.
Every hospital worldwide should utilize the existing re-
sources to create an effective multidisciplinary team for
combating AMR. The best strategies for combating
AMR are not definitively established and are likely to
vary based on local culture, policy, and routine clinical
practice despite several guidelines on the topic.
The Italian situation
In a study published in January 2019 in The Lancet In-
fectious Diseases, the European Center for Disease Pre-
vention and Control (ECDC) assessed the weight of
infections due to multiresistant bacteria in invasive iso-
lates in Europe [40].
Elaborating the 2015 data contained in the European
Antimicrobial Resistance Surveillance Network (EARS-
Net) and crossing them with a conversion factor, the au-
thors arrived at the first estimate of the impact of
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antibiotic resistance on the European population. The
authors estimate that infections caused by multiresistant
bacteria can cause at least 33,000 deaths each year in
Europe (equal to the sum of deaths caused by influenza,
AIDS, and tuberculosis) and almost 880.000 cases of dis-
ability. Italy and Greece have the most infections from
multiresistant bacteria. Although we consider that the
Italian population is of a medium-high age, it is note-
worthy that about a third of deaths due to antibiotic-
resistant bacterial infections in Europe have been in
Italy. Not surprisingly, in December 2017, the ECDC
published a report on the Italian situation and activities
for the prevention and control of antibiotic resistance
[41]. The report summarizes visits and meetings that
ECDC experts had in Italy from January 9 to 13, 2017,
to discuss and specifically assess the situation in the
country regarding antibiotic-resistance prevention and
control in our country. Observations of this visit by the
ECDC confirm that the antibiotic resistance situation in
Italian hospitals will represent a serious threat to public
health for the country in the near future.
ECDC experts noted the following:
 Little sense of urgency about the current AMR
situation from most stakeholders and a tendency by
many stakeholders to avoid taking charge of the
problem
 Lack of institutional support at the national,
regional, and local level
 Lack of professional leadership at each level
 Lack of accountability at each level
 Lack of coordination of the activities between and
within levels
According to a report by the Organization for Eco-
nomic Co-operation and Development (OECD) [42], in
Italy, the proportion of antibiotic-resistant infections
have grown from 17% in 2005 to 30% in 2015 and will
reach 32% in 2030, if antibiotic consumption will con-
tinue to follow the same trends. The proportion of anti-
biotic resistance in Italy is substantially higher than that
in the 17% average resistance of OECD countries in
2015.
On November 2, 2017, the Ministry of Health pub-
lished the national anti-microbial resistance plan
(PNCAR) 2017–2020 [43], which identified strategies
and actions to be implemented at different levels: na-
tional, regional, and local. The PNCAR is developed ac-
cording to a One Health approach. The actions set out
in the plan, at the level of central, regional, and local in-
stitutions, pursue specific objectives:
 Improve awareness and education of health
professionals, citizens, and stakeholders
 Monitor the phenomenon of antibiotic resistance
and the use of antibiotics
 Improve IPC
 Optimize the use of antimicrobials in the field of
human and animal health
 Increase and support research and innovation.
Appropriate management of infections across the
surgical pathway
Antibiotics can be life-saving when treating bacterial in-
fections but are often used inappropriately. Although
most clinicians are aware of the problem of AMR, most
underestimate this problem in their own hospital. Clini-
cians should always optimize antimicrobial management
to maximize the clinical outcome of the patients and
minimize the emergence of AMR. The necessity of for-
malized systematic approaches to the optimization of
antibiotic therapy in the setting of surgical units world-
wide, both for elective and emergency admissions, has
become increasingly urgent.
Below, we report 11 strategies for a correct antibiotic
therapy.
1. Communication and education.
2. Updating local epidemiological data stratifying them
for specific settings.
3. Start and choice treatment always using a severity
driven approach.
4. Drafting local algorithms / bundles.
5. Avoid redundant prescriptions.
6. Not being impulsive in starting antimicrobial
therapy.
7. Being parsimonious with combination regimens.
8. Strict collaboration with microbiology laboratory in
daily life.
9. Being aware about PK/PD issues.
10. Shortening therapy.
11. Creating a multidisciplinary team for specific
setting, syndromes, etc.
Hospital-based programs dedicated to improving anti-
biotic use, commonly referred to as Antimicrobial steward-
ship programs (ASPs), can both optimize the treatment of
infections and minimize adverse events associated with
antibiotic use and AMR [44, 45]. Every hospital worldwide
should utilize the existing resources to create an effective
multidisciplinary team. The preferred means of improving
antibiotic stewardship should involve a comprehensive pro-
gram that incorporates collaboration between various spe-
cialties within a healthcare institution including infectious
disease specialists, hospital pharmacists, clinical pharmacol-
ogists, administrators, epidemiologists, IPC specialists, mi-
crobiologists, surgeons, anesthesiologists, intensivists, and
underutilized but pivotal stewardship team members, the
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surgical, anesthetic, and intensive care nurses in our
hospitals.
Antimicrobial stewardship policies should be based on
both international and national antibiotic guidelines and
tailored to local microbiology and resistance patterns.
Facility-specific treatment recommendations, based on
the guidelines and local formulary options promoted by
the antimicrobial stewardship team, can guide clinicians
in antibiotic selection and duration of the therapy for
the most common indications. Standardizing a shared
protocol of antibiotic prophylaxis should represent the
first step of any ASP. Since physicians are primarily re-
sponsible for the decision to use antibiotics, educating
them and changing the attitudes and knowledge that
underlie their prescribing behavior are crucial for im-
proving antibiotic prescription. Education is fundamen-
tal to every ASP; however, due to cognitive dissonance
(recognizing that action is necessary but not implement-
ing it), changing the prescribing behavior is extremely
challenging [46]. Efforts to improve educational pro-
grams are thus required, and this should preferably be
complemented by active interventions such as prospect-
ive audits and feedback to clinicians to stimulate further
change [47]. It is also crucial to incorporate fundamental
ASP and IPC principles in under- and post-graduate
training at medical faculties to equip young doctors and
other healthcare professionals with the required confi-
dence, skills, and expertise in the field of antibiotic
management.
Question 6. The clinical microbiology laboratory:
which is its role in the control of infections with
multidrug-resistant bacteria?
Statement 6.1. The implementation of microbio-
logical diagnostic activities improves the diagnostic
capacity towards infections caused by multidrug-
resistant organisms (MDROs).
Statement 6.2. The three main challenges of a mod-
ern microbiology laboratory are: to maintain high-
quality services, to consolidate laboratory medical
care into large hospital systems and, as a conse-
quence of consolidation to reach a full automation
possibly in all the analytical steps of the diagnosis.
ASPs and prescribing physicians depend on the infor-
mation and guidance from the clinical microbiology la-
boratory, thus making the laboratory vital to patient care
and the success of ASPs. The three most relevant chal-
lenges of a modern microbiology laboratory are the
following.
Maintaining high-quality and cost-effective services
ASPs aid physicians in providing optimal antimicrobial
therapy to their patients, prescribing the right antimicro-
bial regimen to the right patient for the right period of
time, and avoiding the unnecessary use of antimicrobial.
Ultimately, ASPs aim to improve patient outcomes while
limiting adverse drug events and reducing AMR. The
clinical microbiology laboratory plays a critical role in
the success of the antimicrobial stewardship efforts by
providing essential information for accurately diagnosing
and treating patients with infectious diseases [48].
Clinical microbiology laboratories (CMLs) conduct
surveillance on the local AMR trends among micro-
bial pathogens. The collection, organization, and com-
munication of resistance data culminates could be
summarized in the preparation of the antibiogram.
Antibiograms provide critical information to ASPs
and to prescribing physicians on local institution sus-
ceptibility patterns. CMLs provide patient-specific in-
formation by identifying the microbial pathogens and
performing the antimicrobial susceptibility testing.
This information is necessary so that empiric anti-
microbial therapy can be shortened and substituted
by a pathogen-driven approach. Over the past decade,
there have been several advances in rapid microbio-
logical diagnostic testing. Compared to standard tech-
niques that require 48–72 h for final results, these
methods can greatly reduce the time to pathogen
identification by providing final organism identifica-
tion within hours from the sample collection or, less
efficiently, from the availability of an isolated bacterial
colony by culture-based methods.
Consolidation of laboratory medical care into large
hospital systems: consolidated hospital network systems
open the possibility to merger microbiology diagnostic
activities into larger laboratories
Many new innovative microbiological diagnostic ap-
proaches have been made available during the last 10
years with a major impact on patient care and public
health surveillance [49]. In parallel, to enhance the cost-
effectiveness of the CMLs, European laboratory profes-
sionals have streamlined their organization leading to
the amalgamation of diagnostic activities and thus re-
structuring of their professional relationships with clini-
cians and public health specialists. Through this
consolidation process, an operational model has
emerged that combines large centralized CMLs perform-
ing a large panel and number of tests within a high-
throughput analytical platform connected to several dis-
tal laboratories dealing locally with urgent analyses at
the near point of care testing. The centralization of diag-
nostic services so that encompassing a large geographical
region has given rise to the concept of regional-scale
“microbiology laboratories network” or, in another word
to “geographically spread laboratories.” Although the
volume-driven cost savings associated with such labora-
tory networks seem self-evident, the consequences for
the quality of patient care and infectious disease
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surveillance and control remain a challenge even if the
fast-changing landscape of CMLs in Europe may give a
range of opportunities to contribute to improving the
quality of patient care but also the early detection and
enhanced surveillance of public health threats caused by
infectious diseases.
Full automation is currently being required to meet the
needs of a changing healthcare system based on
consolidated geographically spread microbiology
laboratories
During the last decade, most CMLs have encountered
many management and financial difficulties, mainly
resulting from the gradual and continuous increase in
sample volume with limited budgets and personnel
shortages. Thus, laboratories have been forced to
optimize their workflow to raise their productivity: this
improvement must be accompanied by at least a main-
tained analytical quality, but possibly by an improved
clinical value of the generated data. Automation was in-
troduced many years ago in several diagnostic disciplines
such as chemistry, clinical pathology, and hematology to
increase laboratory productivity and quality. The auto-
mation process was by far more complicated in molecu-
lar biology and bacteriology settings: this was due to
several reasons, including the complexity and variability
of sample types, the many different analytical processes,
and the insufficient volume of samples. However, the
introduction of automation was considered to be also
applicable in microbiology in more recent years thanks
to the technological improvements currently available.
Recently, these new technologies have triggered the de-
velopment of automated solutions specifically designed
for microbiology. In particular, the automation process
has been applied to all the pre-analytical steps and to
the evaluation of the results by using sophisticated artifi-
cial intelligence algorithms. The complete clinical la-
boratory automation is currently the main organizational
challenge for microbiologists [50].
Question 7. How can you manage the patient with
infection/colonization of multidrug-resistant organ-
isms (MDROs)?
Statement 7.1. The application of contact isolation
precautions is always recommended for patients
known or highly suspected for MDROs.
MDROs including methicillin-resistant Staphylococcus
aureus (MRSA), vancomycin-resistant Enterococcus
(VRE), extended-spectrum β-lactamase (ESBL) pro-
ducers, and Klebsiella pneumoniae-producing carbape-
nemase (KPC) pose significant public health challenges.
The prevention and control of MDROs are a global
priority.
Traditionally, hospitals have been considered the main
reservoir of MDROs. Around 20–40% of nosocomial
infections can be mainly attributed to cross-infection via
the hands of healthcare personnel. Less frequently, pa-
tients can become colonized with nosocomial pathogens
by direct contact with contaminated patient care equip-
ment or contaminated surfaces in the healthcare envir-
onment [51].
Current strategies to address MDROs consist of the
three following strategies [52]:
 Developing new antimicrobial agents
 Increasing antimicrobial stewardship efforts
 Interrupting MDROs cross-transmission
Bacteria tend to inhabit specific sites on either in the
human body or in the hospital environment which serve
as reservoirs for transmission. The reservoirs of resistant
organisms include niches in the human microbiome.
The microbiota of the skin, respiratory epithelium, and
the gastrointestinal tract are altered within a few days in
the hospital. Patients’ flora can be deranged by antibi-
otics, chemotherapy, or acquisition of nosocomial organ-
isms. Patients who are colonized with resistant bacteria
serve inadvertently as potential reservoirs for transmis-
sion. Colonization pressure, or the proportion of patients
in a given unit who are colonized with resistant bacteria,
is an independent risk factor for transmission. Surveil-
lance cultures for carbapenem-resistant Enterobacteria-
ceae (CRE) have been advocated in a number of reports
and recommendations as part of an overall strategy to
combat it. Active screening for CRE using rectal sur-
veillance cultures has been shown to be highly effect-
ive, when part of a comprehensive infection control
program, in halting the spread of CRE in healthcare
facilities [53].
Isolation or cohorting of colonized/infected patients is
a cornerstone of IPC. Its purpose is to prevent the trans-
mission of microorganisms from infected or colonized
patients to other patients, hospital visitors, and HCWs,
who may subsequently transmit them to other patients
or become infected or colonized themselves. Isolating a
patient with highly resistant bacteria is beneficial in
stopping the patient-to-patient spread. Isolation mea-
sures should be an integral part of any IPC program;
however, they are often not applied consistently and
rigorously, because they are expensive, time-consuming,
and often uncomfortable for patients.
Facilities should have written policies and procedures
that identify patients with MDROs and should require
that contact precautions are implemented in all practice
settings. Communication is a vital component for suc-
cessful implementation of contact precautions and must
occur at all points in the perioperative process.
Question 8. Antimicrobial stewardship: Is a multi-
disciplinary approach necessary?
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Statement 8.1. The three basic requirements of an
Antimicrobial Stewardship program are:
 The existence of a multidisciplinary
antimicrobial stewardship team.
 A microbiological report on a fixed basis on the
bacterial resistance of the hospital at least
annually, if possible stratified by departments or
at least for some key departments (e.g. Intensive
Care Units).
 A report on fixed consumption of antibiotics in
the hospital.
Statement 8.2. A multidisciplinary antimicrobial
stewardship team should be coordinated by an infec-
tious disease specialist, or by another specialist with
documented infectious skills.
Every hospital worldwide should utilize the existing re-
sources to create an effective multidisciplinary team for
combating AMR. The best strategies for combating
AMR are not definitively established and are likely to
vary based on local culture, policy, organization, and
routine clinical practice despite several guidelines on the
topic [44].
We propose that the best means of improving pro-
grams to contain AMR should involve collaboration
among various specialties within a healthcare institution.
They should focus on collaboration between all health-
care professionals to shared knowledge and widespread
diffusion of practice. The involvement of HCWs may
raise their awareness of AMR [44]. It is essential for any
team to have at least one member who is an infectious
disease specialist. Pharmacists with advanced training or
long-standing clinical experience in infectious diseases
are also key actors for the design and implementation of
the stewardship program interventions monitoring con-
sumption data of antibiotics. In any healthcare setting, a
significant amount of energy should be spent on IPC. In-
fection control specialists and hospital epidemiologists
should be always included in these programs to coordin-
ate efforts on monitoring and preventing HAIs. Microbi-
ologists should actively guide the proper use of tests and
the flow of laboratory results. Being involved in provid-
ing surveillance data on AMR, they should provide peri-
odic reports on AMR data allowing the multidisciplinary
team to determine the ongoing burden of AMR in the
hospital. Moreover, timely and accurate reporting of
microbiology susceptibility test results allows the selec-
tion of more appropriate targeted therapy and may help
reduce broad-spectrum antimicrobial use. Surgeons with
adequate knowledge in surgical infections and surgical
anatomy when involved may audit both antibiotic pre-
scriptions and prevention practices, provide feedback to
the prescribers and integrate best practices of antimicro-
bial use among surgeons, and act as champions among
colleagues implementing change within their own sphere
of influence. Infections are the main factors contributing
to mortality in ICUs. Intensivists have a critical role in
treating multidrug-resistant organisms in ICUs in critic-
ally ill patients. They have a crucial role in prescribing
antimicrobial agents for the most challenging patients
and are at the forefront of successful antibiotic prescrib-
ing policies. Emergency departments (EDs) represent a
particularly important setting for addressing inappropri-
ate antimicrobial prescribing practices, given the fre-
quent use of antibiotics in this setting that sits at the
interface of the community and the hospital. Therefore,
also ED practitioners should be involved. Without ad-
equate support from hospital management, these pro-
grams will be inadequate or inconsistent since the
programs do not generate revenue. Engagement of hos-
pital management has been confirmed as a key factor for
both developing and sustaining. Finally, an essential par-
ticipant who has been often unrecognized and underuti-
lized is the “staff nurse” as nurses perform numerous
functions that are integral to success.
Question 9. Why and how do you have to monitor
antibiotics consumption in the hospitals?
Statement 9.1. It is important to monitor antibi-
otics consumption. The data of the consumption data
of antibiotics should be expressed in specific reports
in defined daily doses.
Pharmacy’s contribution to ASPs has significantly
evolved over the course of the twenty-first century. Al-
though microbiologists and infection specialist physi-
cians have been conventionally responsible for providing
advice on clinical management of infected patients,
many pharmacists in clinical practice have now estab-
lished roles complementing the expertise in multidiscip-
linary antimicrobial stewardship teams.
Pharmacists’ responsibilities for antimicrobial stew-
ardship include promoting the optimal use of anti-
microbial agents. Typical interventions include
patient-specific recommendations on therapy; the im-
plementation of policies, education, therapeutic drug
monitoring, and participation in antimicrobial stew-
ardship ward rounds [54, 55].
Antibiotics are prescribed in up to a third of hospital
inpatients, often inappropriately [56], and more than
two thirds of critically ill patients are on antibiotics at
any given time during their hospital admission [57].
Antibiotic use is one of the most important parameters
for assessing the impact that an ASP has on a hospital
and its patient population, although microbiological re-
sistance and clinical outcomes are also important mea-
sures. Antimicrobial measures looking at consumption
are the most commonly used measures and are focused
on defined daily dose (DDD), usually standardized per
1000 patient-days.
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DDD is a metric that was developed in the 1970s and
has been further refined and promoted by the WHO
Collaborating Centre for Drug Statistics Methodology.
DDD is described as “the assumed average maintenance
dose per day for a drug used for its main indication in
adults” [58]. In simple terms, a DDD is the amount of
drug that a typical patient might receive on any day for
therapeutic purposes. An important advantage of using
DDDs is the relative ease of hospital systems to report
consumption using DDDs: most pharmacy departments
have a mechanism to calculate overall prescription, dis-
pensing, or consumption of a quantity of antimicrobials,
allowing DDDs/1000 patient-days to be relatively easy to
calculate if bed utilization is also available. Additionally,
institution-wide consumption can be benchmarked
against similar institutions. The landmark guidelines on
antimicrobial stewardship by the Infectious Diseases So-
ciety of America and Society for Healthcare Epidemi-
ology of America advocated for DDDs/1000 patient-days
as a universal metric for hospital-based ASPs [59].
Question 10. What is the role for the nurse in pre-
venting HAIs?
Statement 10.1. The nurse is an integral part of the
multidisciplinary team for the prevention of infec-
tions across the surgical pathway.
Statement 10.2. It is important to implement edu-
cational and training interventions concerning the
prevention of SSIs by following a modality appropri-
ate to the level of education of the patient/caregiver.
The role of the professional nurse in preventing HAIs
is significant. The nurse is a member of the healthcare
team who leads the rest of the team in practicing pre-
vention strategies to protect the patient from infection
[60]. Some of the most basic strategies resulting in posi-
tive patient outcomes include the following:
 The practice and promotion of hand hygiene
 Consistent use of aseptic technique
 Cleaning and disinfection practices
 Use of standard precautions
 Patient assessment and additional precautions
 Patient education
 Use of safety devices
 Removal of unnecessary invasive devices
 Use of bundle strategies for infection prevention
 Fit for duty
Nurses play a pivotal role in preventing hospital-
acquired infections (HAIs), not only by ensuring that all
aspects of their nursing practice are evidence-based, but
also through patient education. One of the most import-
ant roles nurses have today is patient education. This
was once reserved for the physician, but no longer.
Today nurses assume more and more responsibility for
educating patients and helping them to become respon-
sible for their own health status. Patients need to take a
proactive role in their own healthcare. This means they
need to comprehend their health status and work to
stabilize and prevent or minimize complications such as
HAIs. Demographic variables, such as formal education
level, reading ability, and barriers to participation in edu-
cation, must be considered to maximize the effectiveness
of self-management education outcomes. Hospital
nurses can best educate patients by understanding that
discharge planning begins with admission. Nurses have
to ensure patients are effectively educated throughout
their hospitalization so that they are prepared to care for
themselves and participate in the care pathway.
Question 11. Which are the principles of antibiotic
prophylaxis?
Statement 11.1. Prolonging antibiotic prophylaxis
after surgery is generally not associated with better
clinical results.
Statement 11.2. There is no universally recognized
intervention for improving the appropriateness of
antibiotic prophylaxis in surgery. These interventions
must be tailored to the type of surgeon and team to
which they are addressed.
Preoperative antibiotic prophylaxis (PAP) has been
demonstrated in multiple randomized controlled trials
and meta-analyses to reduce the risk of SSIs across dif-
ferent types of surgical procedures [61].
Given the evidence, systemic PAP is considered to be
a key component of perioperative infection prevention
bundles [62]. Although compliance with appropriate
timing and spectrum of PAP has improved as a result of
quality improvement initiatives, there remain significant
deficiencies in compliance with other aspects of PAP
such as duration of postoperative antibiotics [63, 64].
Given that approximately 15% of all antibiotics in hospi-
tals are prescribed for surgical prophylaxis [65, 66], peri-
operative antibiotic prescribing patterns can be a major
driver of some emerging infections (such as C. difficile)
[67, 68] and selection of antibiotic resistance, increasing
healthcare costs.
Although appropriate PAP plays a pivotal role in redu-
cing the rate of SSIs [69], other factors that impact SSI
rates should not be ignored. PAP should never substitute
for good medical practices, such as those of IPC. Peri-
operative SSI prevention strategies should include atten-
tion to basic IPC strategies, surgical technique, hospital
and operating room environments, instrument
sterilization processes, and perioperative optimization of
patient risk factors [70].
The key elements of appropriate surgical antimicrobial
prophylaxis prescribing include the correct antimicrobial
indication, drug dose, route, the timing of administra-
tion, and duration.
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Joint guidelines for PAP in surgery were revised
and updated in 2013 by the American Society of
Health-System Pharmacists, Infectious Diseases Soci-
ety of America, Surgical Infection Society, and Society
for Healthcare Epidemiology of America [68]. These
guidelines focus on the effective and safe use of AP.
Therapeutic serum and tissue concentrations of anti-
microbial agents should be present during the period
of potential contamination. Additional antibiotic doses
may need to be administered intraoperatively for pro-
longed procedures or for agents with short half-lives.
In order to be safe, PAP should have no or few ad-
verse effects and should have the narrowest spectrum
of activity necessary to prevent postoperative
infections.
There is no evidence that prolonging PAP after sur-
gery can reduce the risk of SSIs. A single preoperative
dose is adequate for the majority of procedures. Post-
procedural doses of intravenous antibiotics (up to 24 h)
may be only required in defined circumstances, such as
some cardiac and vascular surgeries.
Below, seven practices for a correct surgical antibiotic
prophylaxis are illustrated [71]:
1. Antibiotics alone are unable to prevent SSIs.
Strategies to prevent SSIs should always include
attention to the following:
(a) IPC strategies including correct and compliant
hand hygiene practices
(b) Meticulous surgical techniques and
minimization of tissue trauma
(c) Hospital and operating room environments
(d) Instrument sterilization processes
(e) Perioperative optimization of patient risk factors
(f) Perioperative temperature, fluid, and
oxygenation management
(g) Targeted glycemic control
(h) Appropriate management of surgical wounds
2. Antibiotic prophylaxis should be administered for
operative procedures that have a high rate of
postoperative SSI, or when foreign materials are
implanted.
3. Antibiotics given as prophylaxis should be effective
against the aerobic and anaerobic pathogens most
likely to contaminate the surgical site, i.e., Gram-
positive skin commensals or normal flora colonizing
the incised mucosae.
4. Antibiotic prophylaxis should be administered
within 120 min prior to the incision. However,
administration of the first dose of antibiotics
beginning within 30–60 min before the surgical
incision is recommended for most antibiotics
(e.g., cefazolin), to ensure adequate serum and
tissue concentrations during the period of
potential contamination. Obese patients ≥ 120 kg
require higher doses of antibiotics.
5. A single dose is generally sufficient. Additional
antibiotic doses should be administered
intraoperatively for procedures > 2–4 h (typically
where duration exceeds two half-lives of the anti-
biotic) or with associated significant blood loss (>
1.5 L).
6. There is no evidence to support the use of
postoperative antibiotic prophylaxis.
7. Each institution is encouraged to develop guidelines
for the proper surgical prophylaxis.
Knox and Edye [63] demonstrated that an educational
ASP was ineffective in changing surgical prophylactic
antibiotic prescribing in an Australian hospital. Although
that study was disappointing as far as showing improved
behaviors, others have shown that ASPs may have a sig-
nificant impact on optimizing antibiotic use in surgical
prophylaxis practices [72, 73]. Van Kasteren et al. [73] in
a prospective multisite study of elective procedures in 13
Dutch hospitals evaluated the quality of prophylaxis
auditing before and after an intervention consisting of
performance feedback and implementation of national
clinical practice guidelines. Antimicrobial use decreased
from 121 to 79 DDD/100 procedures, and costs reduced
by 25% per procedure. After the intervention, antibiotic
choice was inappropriate in only 37.5% of the cases in-
stead of 93.5% expected cases in the absence of any
intervention. Prolonged prophylaxis was observed in
31.4% instead of 46.8% expected cases and inappropriate
timing in 39.4% instead of the expected 51.8%. Time
series analysis showed that all improvements were statis-
tically significant (P < 0.01). The overall SSI rates before
and after the intervention were 5.4% (95% CI 4.3–6.5)
and 4.6% (95% CI 3.6–5.4), respectively [73]. Huh et al.
[72] performed an interrupted time-series study of an
ASP relating to surgical prophylaxis in a tertiary care
hospital. The ASP consisted of monitoring of perform-
ance indicators and implementation of a computerized
decision support system. The program was effective in
improving multiple measures including the total use of
antibiotics, the use of third-generation cephalosporins
and aminoglycosides, trends in proportions of resistant
bacterial strains such as meropenem-resistant Pseudo-
monas aeruginosa, and length of stay. Saied et al. [12]
implemented ASPs in 5 tertiary, acute-care surgical hos-
pitals. The ASPs consisted of education aimed at sur-
geons and anesthesiologists, audit and feedback, and
selection of surgeon champions. The efficacy of the
intervention on timing and duration of antibiotic
prophylaxis varied across hospitals when measured pre-
and post-ASP implementation. Local factors such as
available resources and stakeholder engagement likely
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play a role in the conflicting results of ASPs addressing
surgical prophylaxis across different settings, as seen in
these studies.
Question 12. Which are the principles of antibiotic
therapy?
Statement 12.1. It is important to know the local
epidemiological context to define therapeutic proto-
cols / guidelines for surgical infections treatment.
Statement 12.2. It is important to frame clinical
conditions, in particular to differentiate between crit-
ical and non-critical patients.
Statement 12.3. It is important to pursue as much
as possible targeted therapy or in any case a de-
escalation in order to preserve some molecules: e.g.:
carbapenems.
Statement 12.4. It is important to assess properly
the duration of therapy based on source control.
Statement 12.5. In the setting of uncomplicated
intra-abdominal infections including uncomplicated
acute cholecystitis and acute appendicitis post-
operative antimicrobial therapy is not necessary.
Statement 12.6. In patients with complicated intra-
abdominal infections, when patients are not severely
ill and when source control is complete, a short
course (3-5 days) of post-operative therapy is
suggested.
Statement 12.7. In patients with ongoing or persist-
ent intra-abdominal infections, the decision to con-
tinue, revise, or stop antimicrobial therapy should be
made on the basis of clinician judgment and labora-
tory information.
Empirical antibiotic therapy should be based on
local epidemiology, individual patient risk factors for
difficult-to-treat pathogens, clinical severity of infec-
tion, and infection source. Initial antibiotic therapy
for surgical infections is empirical in nature because
microbiological data (culture and susceptibility re-
sults) may require > 24/48 h before they are available
for a more detailed analysis. However, the results
direct expansion of antimicrobial regimen if it is too
narrow and perform a de-escalation if it is too broad
[74, 75], particularly in critically ill patients where
de-escalation strategy is one of the cornerstones of
ASPs [76]. The principles of empiric antibiotic treat-
ment should be defined according to the most fre-
quently isolated microbes, always taking into
consideration the local trend of antibiotic resistance.
In this era of prevalent drug-resistant microorgan-
isms, the threat of resistance is a source of major
concern that cannot be ignored [76].
In the past 20 years, the incidence of intra-abdominal
infections (IAIs) caused by MDROs has risen dramatic-
ally [76]. Quinolone resistance, prevalence of ESBL-
producing bacteria, prevalence and mechanisms of
carbapenem resistance in the local environment, and the
place of recent traveling should be always taken into ac-
count when antibiotic therapy is administered empiric-
ally. Generally, the most important factors in predicting
the presence of resistant pathogens are acquisition in a
healthcare setting (particularly if the patient becomes in-
fected in the ICU or has been hospitalized for more than
1 week), corticosteroid use, organ transplantation, base-
line pulmonary or hepatic disease, and previous anti-
microbial therapy [76, 77].
Previous antibiotic therapy is one of the most important
risk factors for resistant pathogens [78]. Inappropriate
therapy in critically ill patients may have a strong negative
impact on the outcome. An ineffective or inadequate anti-
microbial regimen is one of the variables more strongly as-
sociated with unfavorable outcomes in critically ill
patients. Broad empiric antibiotic therapy should be
started as soon as possible in patients with organ dysfunc-
tion (sepsis) and septic shock [79–83]. International
guidelines for the management of sepsis and septic shock
(the Surviving Sepsis Campaign) recommend intraven-
ously administered antibiotics as soon as possible and in
any case within the first hour of onset of sepsis and the
use of broad-spectrum agents with adequate penetration
of the presumed site of infection [84].
The results of microbiological testing may have great
importance for the choice of therapeutic strategy of
every patient, in particular, in the adaptation of targeted
antibiotic treatment. They provide an opportunity to ex-
pand the antibiotic regimen if the initial choice was too
narrow but also allow de-escalation of antibiotic therapy
if the empirical regimen was too broad. Antibiotic de-
escalation has been associated with lower mortality rates
in ICU patients and is now considered a key practice for
antimicrobial stewardship purposes [75]. The duration
of antibiotic therapy has been studied appropriately in
the setting of intra-abdominal infections (IAIs).
In the event of uncomplicated IAIs, the infection in-
volves a single organ and does not extend to the periton-
eum. When the source of infection is treated effectively
by surgical excision, postoperative antibiotic therapy is
not necessary, as demonstrated in managing uncompli-
cated acute appendicitis or cholecystitis [85–87].
In 2015, an important prospective study on the appro-
priate duration of antibiotic therapy in patients with
complicated IAIs was published [88]. The study random-
ized 518 patients with complicated IAIs and adequate
source control to receive antibiotics until 2 days after the
resolution of fever, leukocytosis, and ileus, with a max-
imum of 10 days of therapy (control group), or to receive
a fixed course of antibiotics (experimental group) for 4 ±
1 calendar days. In patients with complicated IAIs who
had undergone an adequate source control procedure,
the outcomes after fixed-duration antibiotic therapy
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(approximately 4 days) were similar to those after a long
course of antibiotics (approximately 8 days) that ex-
tended until after the resolution of physiological abnor-
malities. In this study, most patients were not severely
ill.
The high mortality associated with abdominal sepsis
requires clinicians to maintain a high index of clinical
suspicion of treatment failure and the early diagnosis of
ongoing infections. These patients should always be
monitored carefully including the potential use of in-
flammatory response markers.
Below, we report 13 practices in an appropriate anti-
biotic therapy across the surgical pathway [71]:
1. The source of infection should always be identified
and controlled as soon as possible.
2. Antibiotic empiric therapy should be initiated after
a treatable surgical infection has been recognized,
since microbiological data (culture and
susceptibility results) may not be available for up to
48–72 h to guide targeted therapy.
3. In critically ill patients, empiric broad-spectrum
therapy to cover all likely pathogens should be initi-
ated as soon as possible after a surgical infection
has been recognized. Empiric antimicrobial therapy
should be narrowed once culture and susceptibility
results are available and/or adequate clinical im-
provement is noted.
4. Empirical therapy should be chosen on the basis of
local epidemiology, individual patient risk factors
for MDR bacteria and Candida spp., clinical
severity, and infection source.
5. Specimens for microbiological evaluation from
the site of infection are always recommended for
patients with hospital-acquired or with
community-acquired infections at risk for resist-
ant pathogens (e.g., previous antimicrobial ther-
apy, prior infection or colonization with a
multidrug-resistant, extensively drug-resistant,
and pan-drug-resistant pathogens) and in critic-
ally ill patients. Blood cultures should be per-
formed before the administration of antibiotics in
critically ill patients.
6. Antibiotics dose should be optimized to ensure that
pharmacokinetic-pharmacodynamic (PK-PD) tar-
gets are achieved. This involves prescribing of an
adequate dose, according to the most appropriate
and right method and schedule to maximize the
probability of target attainment.
7. The appropriateness and need for antimicrobial
treatment should be reassessed daily.
8. Once source control is established, short courses of
antibiotic therapy are as effective as longer courses
regardless of signs of inflammation.
(a) Intra-abdominal infection: 4 days are as effective
as 8 days in moderately ill patients.
(b) Bloodstream infection: 5–7 days are as effective
as 7–21 days for most patients.
(c) Ventilator-associated pneumonia: 8 days are as
effective as 15 days.
9. Failure of antibiotic therapy in patients having
continued evidence of active infection may require
a re-operation for a second source control
intervention.
10. Biomarkers such as procalcitonin (PCT) may be
useful to guide duration and/or cessation of
antibiotic therapy in critically ill patients.
11. Clinicians with advanced training and clinical
experience in surgical infections should be included
in the care of patients with severe infections.
12. IPC measures, combined with ASPs, should be
implemented in surgical departments. These
interventions and programs require regular,
systematic monitoring to assess compliance and
efficacy.
13. Monitoring of antibiotic consumption should be
implemented and feedback provided to all ASP
team members regularly (e.g., every 3–6 months)
along with resistance surveillance data and outcome
measures.
Question 13. How can you manage invasive candid-
iasis in surgical patients?
Statement 13.1. It is important the knowledge of
the risk of developing invasive candidiasis, improve
microbiological diagnostics and optimize treatment.
Invasive candidiasis (IC) has a significant impact on
morbidity, mortality, length of hospital stay, and health-
care costs in critically ill patients [89]. The overall mor-
tality for these patients is high. Candidemia increases
mortality rates in the range of 20–49% [90], and the at-
tributable mortality has been calculated to be around
15% [91]. The severity of illness (APACHE II score > 10,
ventilator use for > 48 h), antibiotics, central venous
lines, total parenteral nutrition, burns, and immunosup-
pression are the most common risk factors [92].
The risk factors for IC are so numerous that most pa-
tients could be considered as exhibiting risk factors for
IC. But, the use of excessive antifungal agents would be
associated with substantially increased overall healthcare
costs and might lead to the emergence of resistance. Un-
fortunately, early diagnosis of IC remains a challenge,
and criteria for starting empirical antifungal therapy in
ICU patients are poorly defined. To both ensure appro-
priate and timely antifungal therapy and to avoid un-
necessary use of antifungal agents, some authors have
developed clinical prediction rules to identify patients at
high risk of candidiasis and for whom initiation of
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empirical antifungal therapy could be justified. However,
there are many concerns about these rules: high specifi-
city but low sensitivity. In 2006, a Spanish group, using
the database of the Estudio de Prevalencia de CANdidia-
sis project, identified four predictors of proven invasive
Candida infection. Based on these predictors, a score
named “Candida score” (CS) was built. In 2009, the same
group demonstrated a significant linear association be-
tween increasing values of the CS and the rate of inva-
sive Candida infections [93]. The factors to predict IC
were surgery, multifocal colonization, total parenteral
nutrition, and severe sepsis. To each risk factor, 1 point
was given, and for clinical sepsis, a score of 2 was given.
The cutoff value of 2.5 had sensitivity of 81% and specifi-
city of 74% [93]. Although blood cultures are still con-
sidered the gold standard for diagnosis, it has been
shown that they are negative in up to 50% of cases [94].
Thus, non-culture diagnostic techniques based on sero-
logical biomarkers detecting fungal cell components
and/or antibodies directed against these components
have been investigated. All these diagnostic tests may
diagnose IC earlier than clinical or culture-based
measures.
Among the biomarkers, mannan antigen and antigen-
antibody complex showed higher sensitivity and specifi-
city when combined together [95]. In a meta-analysis of
14 studies, 7 of which were performed in non-
neutropenic critically ill patients; the sensitivity and spe-
cificity of mannan and anti-mannan IgG were 58% and
93%, and 59% and 83%, respectively. Values for the com-
bined assay were 83 and 86%, with the best perfor-
mances for C. albicans, C. glabrata, and C. tropicalis
infection [95]. The 1,3-beta-D-glucan (BG) is a fungal
cell wall antigen that can be detected in the blood of pa-
tients with a sensitivity of 56–93% and a specificity of
71–100% for IC [96]. Thanks to its high negative pre-
dictive value, BG is potentially useful for the therapy
decision-making process and discontinuing of empirical
antifungal therapy. An integrated strategy with BG and
CS helped to withhold or discontinue treatment, saving
health costs without increasing mortality in 198 severely
ill patients admitted to ICU with sepsis and a CS > 3
[97]. Once the diagnosis is made, early systemic treat-
ment is warranted. The armamentarium of drugs for the
treatment of candidiasis currently comprises 3 major
drug classes: the polyenes, azoles, and echinocandins.
The majority of patients with candidemia have in-
dwelling CVCs when the diagnostic blood culture is
obtained [98], but differentiating between CVC- and
non-CVC-related candidemia is not always straightfor-
ward. C. parapsilosis is particularly frequent as a
cause of CVC infection. There is compelling evidence
that CVC removal is associated with higher rates of
treatment success and lower mortality rates as
compared with CVC retention [98]. Despite contra-
dictory data from a post hoc analysis of 2 clinical tri-
als [98], it is generally accepted that indwelling CVCs
should be removed as early as possible in all patients
with candidemia [99]. CVCs should be urgently re-
moved in patients with septic shock. For clinically
stable patients for whom immediate CVC removal
presents significant difficulties, for example, due to
limited vascular access, establishing a diagnosis of
CVC infection may be of importance.
Question 14. Which are the principles of antibiotic
therapy in critically ill patients?
Statement 14.1. In critically ill patients, antibiotic
therapy should be prescribed using a severity and risk
stratification driven approach.
Statement 14.2. It is important to support the need
for better identification of patients at risk of MDROs
infection, more accurate diagnostic tools enabling a
rule-in/rule-out approach for bacterial sepsis, the use
of adequate dosing and administration schemes to
ensure the attainment of pharmacokinetics/pharma-
codynamics targets, concomitant source control when
appropriate, and a systematic reappraisal of initial
therapy in an attempt to minimize collateral damage
on commensal ecosystems through de-escalation and
treatment-shortening whenever conceivable.
The rapid global spread of multiresistant bacteria and
loss of antibiotic effectiveness increases the risk of initial
inappropriate antibiotic therapy (IAT) and poses a ser-
ious threat to patient safety especially in critically ill pa-
tients. A systematic review and meta-analysis of
published studies to summarize the effect of appropriate
antibiotic therapy or IAT against Gram-negative bacter-
ial infections in the hospital setting was published in
2014 [100]. Using a large set of studies, the authors
found that IAT is associated with a number of serious
consequences, including an increased risk of hospital
mortality.
Infections caused by drug-resistant, Gram-negative or-
ganisms represent a considerable financial burden to
healthcare systems due to the increased costs associated
with the resources required to manage the infection,
particularly longer hospital stays. However, given the im-
pact of early and broad-spectrum empirical therapy and
the emphasis on this in international guidelines, there is
a low threshold for initiating antibiotics in many patients
with suspected infection. This has led to the widespread
use of antibiotics in critically ill patients, which is often
unnecessary or inappropriate [101].
The massive consumption of antibiotics in the ICU is
responsible for substantial ecological side effects that
promote the dissemination of MDROs. Strikingly, up to
half of ICU patients receiving empirical antibiotic ther-
apy have no definitively confirmed infection, while de-
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escalation and shortened treatment duration are insuffi-
ciently considered in those with documented sepsis.
Published data notably support [102] the following:
 The need for better identification of patients at risk
of MDROs infection
 More accurate diagnostic tools enabling a rule-in/
rule-out approach for bacterial sepsis
 An individualized reasoning for the selection of
single-drug or combination empirical regimen
 The use of adequate dosing and administration
schemes to ensure the attainment of PK-PD targets
 Concomitant source control when appropriate
 A systematic reappraisal of initial therapy in an
attempt to minimize collateral damage on
commensal ecosystems through de-escalation and
treatment shortening whenever conceivable
Several trials found PCT-guided antibiotic stewardship
to reduce antibiotic exposure and associated side effects
among patients with respiratory infection and sepsis
[103]. Decisions regarding antibiotic use in an individual
patient are complex and should be based on the pre-test
probability for bacterial infection, the severity of presen-
tation, and the results of the PCT. In the context of a
low pre-test probability for bacterial infections and a
low-risk patient, a low PCT level helps to rule out bac-
terial infection and empiric antibiotic therapy can be
avoided. In the context of a high pre-test probability for
bacterial infections and/or a high-risk patient with sep-
sis, monitoring of PCT over time helps to track the reso-
lution of infection and decisions regarding the early stop
of antibiotic treatment. Although these concepts have
been successful in several respiratory infection and sep-
sis trials, some studies failed to show an added benefit of
PCT due to factors such as low protocol adherence and
relying on single rather than repeat PCT measurements.
In this era of AMR, another interesting strategy is a
therapeutic approach based on patient risk stratification.
Especially for Gram-negative MDRO infections, an ap-
proach based on the patient risk stratification could im-
prove outcomes and avoid antibiotic misuse.
This approach could help physicians to avoid anti-
biotic overuse as well as to start promptly with the most
appropriate antibiotic regimen. Several risk factors for
Gram-negative MDRO infections have been identified.
These include prior infection or colonization with
Gram-negative MDROs, antibiotic therapy in the past
90 days, poor functional status performance,
hospitalization for more than 2 days in the past 90 days,
occurrence five or more days after admission to an acute
hospital, receiving hemodialysis, and immunosuppres-
sion [104]. Moreover, prior receipt of carbapenems,
broad-spectrum cephalosporins, and fluoroquinolones
has been associated specifically with MDR Pseudomonas
aeruginosa [105].
Recently, the high mortality and mortality associated
with multidrug-resistant Gram-negative bacteria along
with limited treatment options have led to a resurgence
in the use of the nephrotoxic drug colistin. Fortunately,
several new antibiotic agents with activity against Gram-
negative MDROs, including ceftazidime/avibactam and
ceftolozane/tazobactam, have become available. Further
studies are needed to elucidate their place in therapy
and their impact on real-world outcomes such as length
of stay and mortality, especially for ICU patients; how-
ever, these are the few resources we have and should not
be wasted unnecessarily.
Question 15. Who is the surgeon champion?
Statement 15.1. To be a champion in preventing
and managing infections in surgery means to create a
culture of collaboration in which infection preven-
tion, antimicrobial stewardship and correct surgical
approach are of high importance.
There is sometimes a false impression that HAIs are
adequately controlled. However, with multidrug-
resistant bacteria increasing, such as MRSA, VRE,
carbapenem-resistant Enterobacteriaceae (CRE), such in-
fections are more than ever a public health threat. It is
well known that HAIs tend to show higher resistance
rates to antibiotics than community-acquired infections.
Patients in hospitals are often exposed to multiple risk
factors for the acquisition of multidrug-resistant bac-
teria. Acute care facilities are important sites for the de-
velopment of AMR. The intensity of care together with
populations highly susceptible to infection creates an en-
vironment that facilitates both the emergence and trans-
mission of resistant organisms.
Surgeons with satisfactory knowledge in surgical in-
fections involved in both IPC team and in the ASPs
may integrate the best practice among surgeons. Al-
though the surgeon’s impact on the incidence of SSIs
has not yet been examined in a comprehensive man-
ner, some reports have reported that the incidence of
SSIs varies widely between hospitals and between sur-
geons [106, 107], suggesting that working practices
play a critical role in the prevention of these infec-
tions and that more may be done to improve infec-
tion control in routine surgical practice.
Very few studies have focused on the relationship be-
tween ASPs and surgeons. In 2015, Çakmakçi [108] sug-
gested that the engagement of surgeons in ASPs might
be crucial to their success. However, in 2013, Duane
et al. [109] showed poor compliance with surgical ser-
vices with ASP recommendations. A retrospective study
by Sartelli et al. [110] showed that implementation of an
education-based ASP achieved a significant improve-
ment in all antimicrobial agent prescriptions and a
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reduction in antimicrobial drug consumption. In a surgi-
cal unit performing mainly elective major abdominal
surgery and emergency surgery, both a local protocol of
surgical prophylaxis and a set of guidelines for the man-
agement of intra-abdominal infections (IAIs) and control
of antimicrobial agent use were introduced. Comparing
the pre-intervention and post-intervention periods, the
mean total monthly antimicrobial use decreased by
18.8%, from 1074.9 defined DDDs per 1000 patient-days
to 873.0 DDDs per 1000 patient-days after the interven-
tion. The model was based on the concept of the “sur-
geon champion.” The “champion” was a surgeon who on
a day-to-day basis worked within the surgical unit, pro-
moting and maintaining a culture in which IPC appro-
priate use of antibiotics was of high importance.
Identifying a local opinion leader to serve as a champion
may be important because the “surgeon champion” may
integrate the best clinical practices and drive the col-
leagues in changing behaviors. We believe that the con-
cept of the “surgeon champion” can be a crucial way to
improve IPC across the surgical pathway.
Question 16. Which are the principles of source
control?
Statement 16.1. The timing and adequacy of source
control are important in the management of surgical
infections; late and/or incomplete procedures may
have severely adverse consequences on outcome espe-
cially in critically ill patients.
Source control encompasses all measures undertaken
to eliminate the source of infection, reduce the bacterial
inoculum, and correct or control anatomic derange-
ments to restore normal physiologic function [111, 112].
As a general principle, every verified source of infec-
tion should be controlled as soon as possible. The level
of urgency of treatment is determined by the affected or-
gans, the relative speed at which clinical symptoms pro-
gress and worsen, and the underlying physiological
stability of the patient. Non-operative interventional pro-
cedures include percutaneous drainages of abscesses.
Ultrasound- and CT-guided percutaneous drainage of
abdominal and extraperitoneal abscesses in selected pa-
tients are safe and effective. The principal cause for fail-
ure of percutaneous drainage is misdiagnosis of the
magnitude, extent, complexity, and location of the ab-
scess [113].
Surgery is the most important therapeutic measure to
control surgical infections. In the setting of intra-
abdominal infections, the primary objectives of surgical
intervention include determining the cause of peritonitis,
draining fluid collections, and controlling the origin of
the abdominal sepsis. In patients with intra-abdominal
infections, surgical source control entails resection or
suture of a diseased or perforated viscus (e.g., diverticu-
lar perforation, gastro-duodenal perforation), removal of
the infected organ (e.g., appendix, gallbladder), debride-
ment of necrotic tissue, resection of ischemic bowel, and
repair/resection of traumatic perforations with primary
anastomosis or exteriorization of the bowel.
In certain circumstances, infection not completely
controlled may trigger an excessive immune response
and local infection may progressively evolve into sepsis,
septic shock, and organ failure. Such patients can benefit
from immediate and aggressive surgical re-operations
with subsequent re-laparotomy strategies, to curb the
spread of organ dysfunctions caused by ongoing periton-
itis. Surgical strategies following an initial emergency
laparotomy include subsequent “re-laparotomy on de-
mand” (when required by the patient’s clinical condition)
as well as planned re-laparotomy in the 36–48h postop-
erative period [114].
On-demand laparotomy should be performed only
when absolutely necessary and only for those patients
who would clearly benefit from additional surgery.
Planned re-laparotomies, on the other hand, are per-
formed every 36–48 h for purposes of inspection, drain-
age, and peritoneal lavage of the abdominal cavity. The
concept of a planned re-laparotomy for severe peritonitis
has been debated for over 30 years. Re-operations are
performed every 48 h for reassessing the peritoneal in-
flammatory process until the abdomen is free of ongoing
peritonitis; then the abdomen is closed. The advantages
of the planned re-laparotomy approach are optimization
of resource utilization and reduction of the potential risk
for gastrointestinal fistulas and delayed hernias. The re-
sults of a clinical trial published in 2007 by Van Ruler
et al. [115] investigating the differences between on-
demand and planned re-laparotomy strategies in patients
with severe peritonitis found few advantages for the
planned re-laparotomy strategy; however, the study
mentioned that this latter group exhibited a reduced
need for additional re-laparotomies, decreased patient
dependency on subsequent healthcare services, and de-
creased overall medical costs.
An open abdomen (OA) procedure is the best way of
implementing re-laparotomies. Open abdomen (OA)
procedure is defined as intentionally leaving the fascial
edges of the abdomen unapproximated (laparostomy).
The abdominal contents are exposed and protected with
a temporary coverage. The OA technique, when used
appropriately, may be useful in the management of sur-
gical patients with severe abdominal sepsis [116]. How-
ever, the role of the OA in the management of severe
peritonitis is still being debated. The role of the OA in
the management of severe peritonitis has been a contro-
versial issue [116]. Although guidelines suggest not to
routinely utilize the open abdomen approach for patients
with severe intra-peritoneal contamination undergoing
emergency laparotomy for intra-abdominal sepsis, OA
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has now been accepted as a strategy in treating physiolo-
gically deranged patients with acute peritonitis.
Question 17. What is the role of the biomarkers in
surgery?
Statement 17.1. C-reactive protein (CRP) and pro-
calcitonin (PCT) can help clinicians to diagnose sur-
gical infections.
Statement 17.2. PCT can help clinicians in early
discontinuation of antibiotics in critically ill patients
and in patients undergoing intervention for acute
peritonitis.
Although more than a hundred biomarkers have been
studied, only a limited number of them became routinely
available in clinical practice. CRP and PCT are the more
frequently studied and used biomarkers.
Serum CRP is an acute-phase protein synthesized exclu-
sively in the liver. Its secretion is initiated 4 to 6 h after an
inflammatory insult (effect mediated by cytokines namely
interleukin-6), and its concentration doubles every 8 h
with a peak at 36–50 h [117]. The sole determinant of
CRP plasmatic levels is its synthesis rate, which is propor-
tional to the intensity of the inflammatory insult. Its pro-
duction and elimination are not influenced by renal
replacement therapy or immunosuppression (both sys-
temic steroids and neutropenia). It has a sensitivity of 68–
92% and a specificity of 40–67% as a marker of bacterial
infection. Its low specificity and inability to differentiate
bacterial infections from non-infectious causes of inflam-
mation make CRP of limited diagnostic value [118]. The
available assays for CRP measurement are reliable, stable,
reproducible, rapid, inexpensive, and present an ac-
ceptable limit of detection (0.3–5 mg/L). CRP has
been analyzed in multiple clinical contexts, but only
a small number of studies have focused on its use
for optimizing antibiotic therapy [119]. In primary
care, CRP improves the assessment of the severity
of infection and extent of inflammation [120] and
performs better in predicting the diagnosis of pneu-
monia than any individual or combination of clinical
signs and symptoms. A Cochrane review [121] dem-
onstrated reduced antibiotic prescription with CRP
testing, which led to its incorporation in the Na-
tional Institute for Health and Care Excellence
(NICE) guidelines for the diagnosis of pneumonia.
CRP has been reported to be useful in the diagnosis
of appendicitis; however, it lacks specificity. Mul-
tiple studies have examined the sensitivity of CRP
level alone for the diagnosis of appendicitis in pa-
tients selected to undergo appendectomy. Gurleyik
et al. noted a CRP sensitivity of 96.6% in 87 of 90
patients with a histologically proven disease [122].
Similarly, Shakhatreh found a CRP sensitivity of
95.5% in 85 of 89 patients with histologically proven
appendicitis [123]. Asfar et al. reported a CRP
sensitivity of 93.6% in 78 patients undergoing
appendectomy [124].
PCT is a precursor protein of calcitonin that can be
produced ubiquitously throughout the body. It is re-
leased 3–4 h after an inflammatory stimulus with a plas-
matic peak within 6–24 h and a half-life ranging from 22
to 35 h. Its plasmatic levels are markedly influenced by
renal function, different techniques of renal replacement
therapy, and neutropenia. It showed a sensitivity of 77%
and a specificity of 79% for early diagnosis of sepsis in
critically ill patients [117, 118]. PCT is the most widely
studied biomarker for antibiotic stewardship. It has been
tested as an aid to the initiation and/or discontinuation
of antibiotics, both in children and adults presenting
with distinct sources of infection and in different scenar-
ios. Multiple trials have investigated the benefits of using
serum PCT levels to guide whether and for how long
antibiotic therapy is used—a process referred to as a
PCT-guided antibiotic stewardship—in patients with in-
fection in the ICU [125–135]. Several studies have dem-
onstrated the benefits of using serum PCT levels to
guide antibiotic therapy in patients undergoing interven-
tion for acute peritonitis [136, 137].
Question 18. Who are the patients at high risk for
surgical site infections?
Statement 18.1. A number of risk factors are known
to increase the incidence of SSIs, they can be effect-
ive at three different levels: patient, operative (surgi-
cal procedure-related) and institutional level
(hospital related).
Statement 18.2. Although multiple strategies exist
for identifying surgical patients at high risk for SSIs,
no one strategy is superior for all patients and fur-
ther efforts are necessary to determine if risk stratifi-
cation in combination with risk modification can
reduce SSIs in this patients’ population.
SSIs are a significant healthcare quality issue, result-
ing in increased morbidity, disability, length of stay,
mortality, resource utilization, and costs. Identification
of high-risk patients may improve preoperative coun-
seling, inform resource utilization, and allow modifi-
cations in perioperative management to optimize
outcomes.
Many risk factors are beyond practitioner control, but
optimizing perioperative conditions can certainly help de-
crease infection risk [138]. High-risk surgical patients may
be identified on the basis of individual risk factors or com-
binations of factors. In particular, statistical models and
risk calculators may be useful in predicting infectious
risks, both in general and for SSIs. These models differ in
the number of variables: inclusion of preoperative, intra-
operative, or postoperative variables; ease of calculation;
and specificity for particular procedures. Furthermore, the
models differ in their accuracy in stratifying risk.
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Although multiple strategies exist for identifying surgi-
cal patients at high risk for SSIs, no strategy is superior for
all patients, and further efforts are necessary to determine
if the risk stratification in combination with risk modifica-
tion can reduce SSIs in this patient population [138].
Early evaluation of perioperative SSI risk factors and
patient risk stratification could be of great value in the
development of predictive risk models [139]. Predictive
risk models could, in turn, assist surgeons and their pa-
tients in the clinical decision-making process (e.g., coun-
seling patients on the appropriateness and risks of
surgery). In addition, risk models could be used to de-
velop targeted perioperative prevention strategies and
diagnostic care process models and improve risk adjust-
ment for risk modeling used in the public reporting of
SSI as a quality metric [139].
However, a study reviewing SSIs in patients undergo-
ing colorectal resections (C-SSIs), identified from an in-
stitutional ACS-NSQIP dataset (2006 to 2014), showed
that published risk prediction models do not accurately
predict C-SSI in their own independent institutional
dataset [140]. Application of externally developed pre-
diction models to any individual practice must be vali-
dated or modified to account for the institution and
case-mix specific factors. This questions the validity of
using externally or nationally developed models for “ex-
pected” outcomes and interhospital comparisons.
Question 19. How can you care post-operative
wounds to prevent surgical site infections?
Statement 19.1. Advanced dressing of any type
should not be used for primarily closed surgical
wounds for the purpose of preventing SSI.
Statement 19.2. The surgical wound dressing can
be removed for a minimum of 48 hours after surgery
unless leakage occurs. There is no evidence that ex-
tending medication time implies a reduction in SSIs.
Appropriate surgical wound and incision management
in the postoperative time period is imperative to prevent
SSIs. The term “surgical wound” used in this document
refers to a wound created when an incision is made with
a scalpel or other sharp cutting device and then closed
in the operating room by suture, staple, adhesive tape, or
glue and resulting in a close approximation of the skin
edges [141]. It is traditional to cover such wounds with a
dressing, which acts as a physical barrier to protect the
wound from contamination from the external environ-
ment until it becomes impermeable to microorganisms.
To assess the effects of wound dressings compared
with no wound dressings, and the effects of alternative
wound dressings, in preventing SSIs in surgical wound
healing by primary intention, a Cochrane review was
published in 2016 [142]. The authors concluded that it
is uncertain whether covering surgical wound healing by
primary intention with wound dressings reduces the risk
of SSI, or whether any particular wound dressing is more
effective than others in reducing the risk of SSI, improv-
ing scarring, reducing pain, improving acceptability to
patients, or is easier to remove. Most studies in this re-
view were small and at a high or unclear risk of bias.
Based on the current evidence, decision-makers may
wish to base decisions about how to dress a wound fol-
lowing surgery on dressing costs as well as patient
preference.
The WHO Global Guidelines for the Prevention of
SSIs [5, 6] suggest not using any type of advanced dress-
ing over a standard dressing on primarily closed surgical
wounds for the purpose of preventing SSI. Low-quality
evidence from ten RCTs shows that advanced dressings
applied on primarily closed incisional wounds do not
significantly reduce SSI rates compared to standard
wound dressings. Postoperative care bundles recom-
mend that surgical dressings be kept undisturbed for a
minimum of 48 h after surgery unless leakage occurs
[143, 144].
Question 20. How can we engage surgeons in ap-
propriate infection prevention and management?
Statement 20.1. Active education techniques, such
as academic detailing, consensus building sessions
and educational workshops, should be implemented
in each hospital worldwide according to its own
resources.
Statement 20.2. Surgeons with satisfactory know-
ledge in surgical infections should be involved in the
infection control team and recognized as “cham-
pions” by the hospital's administration.
Surgeons should be involved in guideline development,
and their implementation should translate practice recom-
mendations into a protocol or pathway that specifies and
coordinates responsibilities and timing for particular ac-
tions among a multidisciplinary team. Although both the
WHO [5, 6] and CDC [7] have recently published guide-
lines for the prevention of SSIs, knowledge and awareness
of IPC measures among surgeons are often inadequate
and a great gap exists between the best evidence and clin-
ical practice with regards to SSI prevention.
Education is crucial in improving HCW behaviors to-
wards HAIs. Effective prevention and management of
HAIs is a process requiring a fundamental understand-
ing of the evolving relationship between inappropriate
prevention and management and the prevalence of HAIs
and the emergence of AMR. However, because medical
professionals have already established their knowledge,
attitudes, and behaviors, it is difficult to change their
deeply established views and behaviors. Increasing
knowledge may influence their perceptions and motivate
them to change behavior. Education and training repre-
sent an important component for the accurate imple-
mentation of recommendations. Education of all health
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professionals in preventing HAIs should begin at the
undergraduate level and be consolidated with further
training throughout the postgraduate years. Hospitals
are responsible for educating clinical staff about IPC
programs. Active education techniques, such as aca-
demic detailing, consensus building sessions and educa-
tional workshops, should be implemented in each
hospital worldwide according to its own resources. Ef-
forts to improve educational programs are required, and
it is necessary that every hospital worldwide develops ap-
propriate educational programs to drive HCWs towards
correct behaviors in the prevention and management of
HAIs. The purpose of training and educating healthcare
professionals should be to ensure both individual under-
standing and a team approach with shared knowledge,
skills, and attitudes towards the prevention and manage-
ment of HAIs.
Peer-to-peer role modeling and champions on an
interpersonal level have been shown to positively influ-
ence the implementation of infection control practices.
Many practitioners use educational materials or didactic
continuing medical education sessions to keep up to
date. However, these strategies might not be very effect-
ive in changing practice, unless education is interactive
and continuous and includes discussion of evidence,
local consensus, feedback on performance (by peers),
and making personal and group learning plans. Identify-
ing a local opinion leader to serve as a champion may be
important because the “champion” may integrate best
clinical practices and drive the colleagues in changing
behaviors, working on a day-to-day basis, and promoting
a culture in which IPC is of high importance. Surgeons
with satisfactory knowledge in surgical infections may
provide feedback to the prescribers, integrate the best
practices among surgeons and implement changes
within their own sphere of influence interacting directly
with the IPC team.
Raising awareness of IPC to stakeholders is another
crucial factor in changing behaviors. Probably, clinicians
are more likely to comply with the guidelines when they
have been involved in developing the recommendations.
One way to engage health professionals in guideline de-
velopment and implementation is to translate practice
recommendations into a protocol or pathway that speci-
fies and coordinates responsibilities and timing for par-
ticular actions among a multidisciplinary team.
Conclusions
Leading international organizations, such as the WHO,
acknowledge that collaborative practice is essential for
achieving a concerted approach to providing care [1].
Prevention and management of infections across the sur-
gical pathway should always focus on the collaboration
between all healthcare professionals with shared
knowledge and widespread diffusion of best practice. In
the Appendix, the statements approved with an agree-
ment ≥ 80% are reported.
Appendix
Statements approved with an agreement ≥80%
Question 1. How can you implement global guidelines
for the prevention of surgical site infections (SSIs)?
Statement 1.1. Recent global guidelines for the pre-
vention of SSIs can support healthcare workers to de-
velop or strengthen infection prevention and control
programs, with a focus on surgical safety, as well as
AMR action plans. All healthcare workers should adopt
these evidence-based recommendations in their clinical
practice.
Statement 1.2. A safer surgical care requires a range
of precautions aimed at reducing the risk of SSIs before,
during and after surgery.
Statement 1.3. To support local implementation of
guidelines for the prevention of SSIs, 5 steps of a multi-
modal strategy, including system change, training and
education, evaluation and feedback, communications for
awareness raising and institutional safety climate and
culture are suggested.
Question 2. Why do you have to survey HAIs?
Statement 2.1. Surveillance of HAIs improves the
quality of care because it reduces the risk of infection. It
should be supported by all healthcare workers.
Question 3. How can you implement the prevention of
HAIs?
Statement 3.1. It is necessary to set up a solid and
branched surveillance network gathering alert signals,
verifying their severity and initiating the organizational
response via “warnings”.
Statement 3.2. The collection and analysis of moni-
toring data serve to identify vulnerabilities in the system.
This is the basis for organizational improvement, risk re-
duction, and damage control.
Question 4. How can you prevent and manage Clostri-
dioides difficile infection (CDI)?
Statement 4.1. Key points forCDI prevention are:
 Antimicrobial stewardship.
 Contact precautions.
 Hand washing (soap, not alcohol).
 Avoid unnecessary gastric acid suppressants.
Statement 4.2. Key points for CDI treatment are:
 Stop unnecessary antibiotics.
 Metronidazole (mild episodes).
 Oral/intracolonic vancomycin.
 Oral fidaxomicin.
 IV bezlotoxumab (recurrent episodes).
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 Fecal microbiota transplantation.
Question 5. How can you prevent central-venous
catheter-related infections?
Statement 5.1. The most effective means to reduce to
the minimum possible central-venous catheter-related
infections are represented by a «bundles» management,
based on the guidelines, implemented with training and
motivational meetings aimed at increasing compliance of
healthcare workers (better if organized in a dedicated
team) and applied by checklist.
Question 6. The clinical microbiology laboratory: which
is its role in the control of infections with multidrug-
resistant bacteria?
Statement 6.1. The implementation of microbiological
diagnostic activities improves the diagnostic capacity to-
wards infections caused by multidrug-resistant organ-
isms (MDROs).
Statement 6.2. The three main challenges of a mod-
ern microbiology laboratory are: to maintain high-
quality services, to consolidate laboratory medical care
into large hospital systems and, as a consequence of con-
solidation to reach a full automation possibly in all the
analytical steps of the diagnosis.
Question 7. How can you manage the patient with in-
fection/colonization of multidrug-resistant organisms
(MDROs)?
Statement 7.1. The application of contact isolation
precautions is always recommended for patients known
or highly suspected for MDROs.
Question 8. Antimicrobial stewardship. Is a multidis-
ciplinary approach necessary?
Statement 8.1. The three basic requirements of an
Antimicrobial Stewardship program are:
 The existence of a multidisciplinary antimicrobial
stewardship team.
 A microbiological report on a fixed basis on the
bacterial resistance of the hospital at least annually,
if possible stratified by departments or at least for
some key departments (e.g. Intensive Care Units).
 A report on fixed consumption of antibiotics in the
hospital.
Statement 8.2. A multidisciplinary antimicrobial stew-
ardship team should be coordinated by an infectious dis-
ease specialist, or by another specialist with documented
infectious skills.
Question 9. Why and how do you have to monitor anti-
biotics consumption in the hospitals?
Statement 9.1. It is important to monitor antibi-
otics consumption. The data of the consumption
data of antibiotics should be expressed in specific
reports in defined daily doses.
Question 10. What is the role for the nurse in prevent-
ing HAIs?
Statement 10.1. The nurse is an integral part of the
multidisciplinary team for the prevention of infections
across the surgical pathway.
Statement 10.2. It is important to implement educa-
tional and training interventions concerning the preven-
tion of SSIs by following a modality appropriate to the
level of education of the patient/caregiver.
Question 11. Which are the principles of antibiotic
prophylaxis?
Statement 11.1. Prolonging antibiotic prophylaxis
after surgery is generally not associated with better clin-
ical results.
Statement 11.2. There is no universally recognized
intervention for improving the appropriateness of anti-
biotic prophylaxis in surgery. These interventions must
be tailored to the type of surgeon and team to which
they are addressed.
Question 12. Which are the principles of antibiotic
therapy?
Statement 12.1. It is important to know the local epi-
demiological context to define therapeutic protocols /
guidelines for surgical infections treatment.
Statement 12.2. It is important to frame clinical con-
ditions, in particular to differentiate between critical and
non-critical patients.
Statement 12.3. It is important to pursue as much
as possible targeted therapy or in any case a de-
escalation in order to preserve some molecules: e.g.:
carbapenems.
Statement 12.4. It is important to assess properly the
duration of therapy based on source control.
Statement 12.5. In the setting of uncomplicated intra-
abdominal infections including uncomplicated acute
cholecystitis and acute appendicitis post-operative anti-
microbial therapy is not necessary.
Statement 12.6. In patients with complicated intra-
abdominal infections, when patients are not severely
ill and when source control is complete, a short
course (3-5 days) of post-operative therapy is
suggested.
Statement 12.7. In patients with ongoing or persistent
intra-abdominal infections, the decision to continue, re-
vise, or stop antimicrobial therapy should be made on
the basis of clinician judgment and laboratory
information.
Question 13. How can you manage invasive candidiasis
in surgical patients?
Statement 13.1. It is important the knowledge of the
risk of developing invasive candidiasis, improve micro-
biological diagnostics and optimize treatment.
Question 14. Which are the principles of antibiotic
therapy in critically ill patients?
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Statement 14.1. In critically ill patients, antibiotic
therapy should be prescribed using a severity and risk
stratification driven approach.
Statement 14.2. It is important to support the need
for better identification of patients at risk of MDROs
infection, more accurate diagnostic tools enabling a
rule-in/rule-out approach for bacterial sepsis, the use
of adequate dosing and administration schemes to
ensure the attainment of pharmacokinetics/pharma-
codynamics targets, concomitant source control
when appropriate, and a systematic reappraisal of
initial therapy in an attempt to minimize collateral
damage on commensal ecosystems through de-
escalation and treatment-shortening whenever
conceivable.
Question 15. Who is the surgeon champion?
Statement 15.1. To be a champion in preventing and
managing infections in surgery means to create a culture
of collaboration in which infection prevention, anti-
microbial stewardship and correctsurgical approach are
of high importance.
Question 16. Which are the principles of source
control?
Statement 16.1. The timing and adequacy of source
control are important in the management of surgical in-
fections; late and/or incomplete procedures may have se-
verely adverse consequences on outcome especially in
critically ill patients.
Question 17. What is the role of the biomarkers in
surgery?
Statement 17.1. C-reactive protein (CRP) and procal-
citonin (PCT) can help clinicians to diagnose surgical
infections.
Statement 17.2. PCT can help clinicians in early dis-
continuation of antibiotics in critically ill patients and in
patients undergoing intervention for acute peritonitis.
Question 18. Who are the patients at high risk for sur-
gical site infections?
Statement 18.1. A number of risk factors are known
to increase the incidence of SSIs, they can be effective at
three different levels: patient, operative (surgical
procedure-related) and institutional level (hospital
related).
Statement 18.2. Although multiple strategies exist for
identifying surgical patients at high risk for SSIs, no one
strategy is superior for all patients and further efforts are
necessary to determine if risk stratification in combin-
ation with risk modification can reduce SSIs in this pa-
tients’ population.
Question 19. How can you care post-operative wounds
to prevent surgical site infections?
Statement 19.1. Advanced dressing of any type should
not be used for primarily closed surgical wounds for the
purpose of preventing SSI.
Statement 19.2. The surgical wound dressing can be
removed for a minimum of 48 hours after surgery unless
leakage occurs. There is no evidence that extending
medication time implies a reduction in SSIs.
Question 20. How can we engage surgeons in appropri-
ate infection prevention and management?
Statement 20.1. Active education techniques, such as
academic detailing, consensus building sessions and edu-
cational workshops, should be implemented in each hos-
pital worldwide according to its own resources.
Statement 20.2. Surgeons with satisfactory knowledge
in surgical infections should be involved in the infection
control team and recognized as “champions” by the hos-
pital’s administration.
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